S described by Kostmann.' This disorder of myelopoiesis is characterized by an impairment of myeloid differentiation on the level of promyelocytes in bone marrow with absolute neutrophil counts (ANC) below 2001 pL in peripheral blood.'-6 Patients with cyclic neutropenia (CN) have regular periods of between 19 and 22 days during which time they spend 4 days or longer with neutrophils less than 20O/pL.'s8 Patients affected by SCN or CN suffer from frequent episodes of severe bacterial infections starting in the first months of life. Clinical trials with recombinant human granulocyte colony-stimulating factor (rhG-CSF) have been initiated in these patients. ' ." In our clinic we have treated 32 SCN patients and four CN patients with rhG-CSF to date. Thirty of the 32 patients with SCN responded to rhG-CSF with an increase in ANC of above 1,000/ kL9.'O; however, the doses needed to achieve this response were heterogenous (3 to 120 pg/kg/d). All four patients with CN responded to rhG-CSF at a dose of 3 pg/kg/d with a shortening of the duration of neutropenia in each cycle, and an increase of the ANC at the neutrophil nadir to above 500/pL.'3 These pharmacologic doses of rhG-CSF would increase the ANC in healthy individuals or other patients to above 3O,OOO/pL, suggesting a defective response of neutrophil precursors from SCN and CN patients to rhG-CSF. In previous studies, we have shown that these patients have no defect in production of G-CSF by monocytes.I4 In addition, SCN patients have increased serum levels of biologically active G-CSF before treatment with rhG-CSF." CN expressed 350 to 1,600 binding sites per cell. The affinity of rhG-CSF to its receptor was similar in patients and controls. These data suggest that SCN patients and CN patients are not defective in G-CSF receptor expression as judged by the numbers of G-CSF binding sites and binding affinity; however, we cannot exclude defects in parts of the G-CSF receptor that may be involved in the signal transduction pathway.
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In this study, we describe the G-CSF receptor expression of neutrophils from patients with SCN and CN during G-CSF treatment. The murine and human G-CSF receptors have recently been cloned'"'* and biochemically characterized." The G-CSF receptor is a glycoprotein with a molecular weight of 130 Kd.I9 In our experimental design, neutrophils from healthy individuals express between 480 and 1,210 binding sites per cell.
MATERIALS AND METHODS

Patients.
We have tested five patients with SCN and four patients with CN. The patient characteristics are listed in Table 1 . All patients were diagnosed in the first year of life and had a history of at least one episode of severe bacterial infection per year requiring intravenous antibiotic treatment. There were no signs of bacterial infections at the time of receptor studies.
Ten milliliters of heparinized blood (100 U/mL Heparin Novo, Novo Industrie, Mainz, Germany) was drawn 24 hours after subcutaneous G-CSF administration (before the next dose of rhG-CSF). The blood was mixed with 5 mL Haes-Ethyl-Starch (Plasmasteril, Fresenius, Oberursel, Germany) in a 15-mL glass tube and incubated for 30 minutes at room temperature. The supernatant was layered on 2 mL Ficoll-Paque (Pharmacia, Freiburg, Germany) and centrifuged at 2,000 rpm for 20 minutes. The pellet was immediately resuspended in 5 mL distilled water and 2.5 mL of a 2.7% solution of NaCl to lyse contaminating erythrocytes. Cells were washed twice with RPMI 1640. To remove bound G-CSF (from the neutrophils), cells were then resuspended for 20 seconds in sodium-citrate buffer (10 mmol/L; pH 4.0) and subsequently washed with RPMI 1640.'" Three micrograms of the rhG-CSF analogue Met-Lys-rhG-CSF (kindly provided by Dr L. Souza, Amgen, Thousand Oaks, CA) was radioactively labeled by the method described by Bolton and Hunter" using 1 mCi of iodinated Bolton-Hunter reagent (Amersham, Braunschweig, Germany). '251-G-CSF was separated from other reaction products using a P6-DG desalting column (Biorad), equilibrated with phosphate-buffered saline, containing 0.02% Tween 20 (Biorad, Munich, Germany) and 0.01% NaN,. This procedure resulted in a specific radioactivity of 12.5 pCi/vg protein.
In a total volume of 500 pL RPMI 1640 containing 0.1% gelatin, 4 x lo6 neutrophils were incubated with various concentrations of '251-G-CSF in the range from 100 to 30,000 pmol/L. Identical incubations were performed in the presence of 2.5 pmol/L of unlabeled rhG-CSF. The specific binding was calculated from the difference between counts per minute (cpm) in the absence and presence of unlabeled G-CSF. This mixture was incubated for 1 hour at 37°C. Aliquots of 125 pL
Isolation of neutrophils.
Iodination of recombinant human G-CSF.
G-CSF binding assay. were then layered onto a 125-kL silicon oil cushion and centrifuged. The radioactivity in the pellet and supernatant was counted separately in a gamma counter. The dissociation constant kd and number of binding sites per cell were determined using scatchard analysis?'
RESULTS
Neutrophils from five patients with SCN and four patients with CN during rhG-CSF treatment were investigated for G-CSF receptor expression. The patient characteristics including ANC at the day of feceptor studies are listed in Table 1 . The specific binding of "'1-G-CSF and Scatchard analysis are shown for one patient (F.R.) and one control in Fig 1. Using this method, we detected between 480 and 1,210 G-CSF binding sites per cell with a kd of 8 to 20 x lo-'' mol/L on neutrophils from healthy individuals (n = 6) ( Table 2 ). Neutrophils from all SCN patients expressed increased numbers of G-CSF binding sites in the range from 2,100 to 3,900 per cell ( Table 2 ). The dissociation constant between G-CSF and its receptor was comparable in both patients and healthy subjects (4.5 to 30 x lo-'' mol/L). Neutrophils from four CN patients had 350, 500, 630, and 1,600 binding sites per cell, respectively. Neutrophils from SCN and CN patients were tested during rhG-CSF therapy (Table 1) . To test the individual variability of the receptor expression in one patient (F.R.), binding studies were performed on 2 different days. The number of
DISCUSSION
In this study, we describe G-CSF receptor expression of neutrophils from patients suffering from SCN or CN. Severe congenital neutropenia is characterized by a maturation arrest of neutrophil precursor cells to mature neutrophils at the promyelocyte
For comparison, we also tested the receptor expression of neutrophils from patients with cyclic ne~tropenia.'.~ As G-CSF is the essential growth and differentiation factor for neutrophil precursors, it seemed reasonable to test whether SCN or CN patients have a defect in G-CSF production or in expressiofl of the receptor. Recently, we have demonstrated that monocytes from SCN patients are capable of producing normal amounts of biologically active G-CSF.14 In addition, we found increased serum levels of biologically active G-CSF in SCN patients compared with healthy ~ontroIs.'~ In this study, we investigated the G-CSF receptor expression on neutrophils from patients with SCN or CN. The defective or decreased response of neutrophil precursors from these patients in vitro (CFU-GM and in vivo' l3 suggested that neutrophil precursors or mature neutrophils from these patients might express lower receptor numbers or receptors with an altered affinity to G-CSF. Therefore, we performed binding assays with '=I-rhG-CSF on neutrophils from patients with SCN, CN, and healthy individuals. Using Scatchard analysis (Fig l) , increased numbers of G-CSF binding sites on neutrophils from patients with SCN as compared with healthy persons could be demonstrated (Table 2) . Tyr-Prol-Tyr-G-CSF with a kd of 250 pmol/L. The higher affinity of these G-CSF analogues might be due to the modificatioq of the molecule. In addition, the techniques for radioactive labeling G-CSF were different in these investigations (eg, lactoperoxidase) compared with our technique (Bolton-Hunter). In our study we wanted to show that the kd of G-CSF receptors is not altered in SCN patients as compared with healthy persons. The small number of individuals tested by all investigators does not allow statistical statements qbout the "normal" kd and "normal" number of receptors.
The increased numbers of G-CSF binding sites on neutrophils from SCN patients could be a result of a feedback regulation mechanism via other cytokines released due to the maturation arrest of neutrophil precursors. During rhG-CSF treatment, a partial maturation arrest at the level of prpmyelocytes is still present in these patients. A second hyppthesis for the increased number of G-CSF binding sites is that rhG-CSF treatment might upregulate the number of G-CSF binding sites as has been shown in vitro for other cytokines such as interleukin-2?6 However, neutrophils from patients with CN seem to have normal numbers of G-C$F binding sites even during G-CSF treatment. Neutrophils from CN patients might have changing numbers of G-CSF binding sites depending on the timepoint within the cycle. On the other hand, the "normal" receptor numbers on neutrophils from CN patients might be explained by the complete maturation of neutrophil precursors in these patients and, therefore, no need to overcome a maturation arrest with an increased receptor number as seen in SCN patients.
From this data, we conclude that there is no defect in G-CSF receptor expression on neutrophils from patients with SCN and that the G-CSF receptor is able to bind rhG-CSF with the same affinity as shown for control subjects. However, from this data we cannot exclude that the intracellular portion of the G-CSF receptor might be defective by point mutation or alternative splicing mechanisms of mRNA. Indeed, recently published data about the human G-CSF receptor demonstrated that there are at least three different G-CSF receptor molecules, depending on alternative splicing of the Nothing is known about the quality of signal transduction of these various G-CSF receptor molecules or about the second messenger pathways activated by binding of G-CSF to these receptors. In patients with SCN, the G-CSF receptor remains to be biochemically characterized. Our preliminary results showed that the gene for the G-CSF receptor is not grossly altered as judged by Southern blot analysis of DNA from patients with SCN &arson A, Kyas U, Pietsch T, Welte K unpublished observations, July 1990).
In conclusion, we have demonstrated that the defective response to G-CSF in vitro and in vivo in SCN and CN patients is not due to low G-CSF receptor numbers or binding affinity of G-CSF to its receptor. However, from this data we cannot exclude that neutrophil precursors (eg, promyelocytes) might have decreased receptor numbers even during rhG-CSF therapy.
NOTE ADDED IN PROOF
The transmembrane part of the G-CSF receptor from SCN patients seems not to be altered compared with receptprs from healthy donors as could be shown in sequencing analysis.
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